ImmuCell

ImmuCell Accounts Payable

The Accounts Payable of ImmuCell (ICCC) as of Nov 3, 2026 is 796,286.00 USD. In the previous year, Accounts Payable was 943,637.00 USD — a change of -15.62% (lower).

Accounts Payable

796,286.00USD

YoY

-15.62%

Last updated:

Accounts Payable of ImmuCell is 2025 796,286.00 USD. Accounts Payable of ImmuCell was 2024 943,637.00 USD. It decreases by -15.62% lower compared to the previous year.

The ImmuCell Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
603,743.00 USD
Jan 1, 2019
572,178.00 USD
Jan 1, 2020
602,347.00 USD
Jan 1, 2021
745,044.00 USD
Jan 1, 2022
789,997.00 USD
Jan 1, 2023
887,733.00 USD
Jan 1, 2024
943,637.00 USD
Jan 1, 2025
796,286.00 USD
The ImmuCell Accounts Payable history
YEARAccounts PayableYoY
796,286.00USD-15.62%
943,637.00USD+6.30%
887,733.00USD+12.37%
789,997.00USD+6.03%
745,044.00USD+23.69%
602,347.00USD+5.27%
572,178.00USD-5.23%
603,743.00USD-50.59%
1.22 MUSD-18.94%
1.51 MUSD+651.32%
200,615.00USD-56.02%
456,193.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Accounts Payable of ImmuCell is 796,286.00 USD in 2025.

Accounts Payable of ImmuCell changed from 943,637.00 USD to 796,286.00 USD, representing a -15.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's ImmuCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ImmuCell

All Key Metrics — ImmuCell